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Objectives. We sought to elucidate the flow-function relation in
chronic postischemic dysfunction during vasodilator stress.
Background. In patients with ischemia and regional dysfunc-
tion, stress echocardiography can elicit three responses in the
dysfunctioning segments: no change, improvement or worsening.
The physiology underlying these responses is unclear.
Methods. Seventeen patients with ischemia and left ventricular
dysfunction underwent evaluation of regional function by two-
dimensional echocardiography and myocardial blood flow by
positron emission tomography and 13N-ammonia. Flow (ml/min
per g) and function (regional wall motion score [RWMS] from
1 5 normal to 4 5 dyskinetic) were evaluated both at rest and
after dipyridamole (0.56 mg/kg body weight over 4 min).
Results. In 45 normal segments, rest to dipyridamole flow
increased from 0.83 6 0.22 (mean 6 1 SD) to 1.87 6 0.90 (p <
0.01) with a hyperkinetic contraction pattern. Among dysfunction-
ing segments, responders (n 5 11) showed an upsloping flow-
function curve during stress (i.e., increased function [RWMS rest
2.5 6 0.5 vs. dipyridamole 1.2 6 0.4] and increased flow [rest
0.69 6 0.30 vs. dipyridamole 1.89 6 1.43, p < 0.01]); nonre-
sponders (n 5 20) had a flat flow-function curve during dipyrid-
amole (i.e., fixed function [RWMS rest and dipyridamole 2.6 6
0.5] and no flow increase [rest 0.64 6 0.24 vs. dipyridamole 0.87 6
0.51, p 5 NS): Ischemic segments (n 5 9) exhibited a downsloping
flow-function curve during dipyridamole (i.e., worsened function
[RWMS rest 2 6 0.5, dipyridamole 3.1 6 0.6] and no significant
flow change [rest 0.67 6 0.29 vs. dipyridamole 0.79 6 0.23, p 5
NS]).
Conclusions. Myocardial segments with rest dysfunction and a
contractile reserve elicitable by a vasodilator stress more often
exhibit residual flow reserve, whereas segments with a fixed or
worsening mechanical response during stress show a flat flow
response.
(J Am Coll Cardiol 1997;30:65–70)
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In patients with chronic coronary artery disease and reduced
regional function, pharmacologic stress echocardiography can
elicit three distinct responses in the basally dysfunctioning
segment: no change (“necrotic” pattern); improvement in
function (“viable” pattern); worsening in function (“ischemic”
pattern) (1).
The physiology underlying these responses is, however,
unclear and largely hypothetical (2), although it has been
speculated that during chronic ischemia there is a rightward
shift of the normal flow-function curve, with a greater reduc-
tion in function occurring for any given reduction of flow (3).
In a previous study, we (4) assessed the relation during
coronary vasodilator stress between regional wall motion and
coronary flow reserve in patients with single-vessel disease and
no myocardial infarction. However, no data on flow-function
correlation during coronary vasodilation are available in pa-
tients with chronic coronary artery disease and reduced re-
gional function. Such data are crucial to understanding clinical
findings in the context of defined pathophysiologic principles,
since it is widely accepted that medicine without physiology is
merely phenomenology (3). The present study was designed to
assess the flow-function correlates during coronary vasodilator
stress of 17 patients with chronic coronary artery disease and
reduced regional function. Regional function was evaluated by
two-dimensional echocardiography, and regional flow by
positron emission tomography (PET) and 13N-ammonia,
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matched on a segment by segment basis, both at rest and after
a low dose (0.56 mg/kg over 4 min) dipyridamole stress.
Methods
Study patients. We studied 17 patients (13 men, 4 women,
mean age 6 SD 59 6 7 years) with a history of chest pain with
myocardial ischemia documented by electrocardiogram
(ECG), or previous myocardial infarction, or both. Eleven of
these patients were included in a previous study (5) (that did
not include stress echocardiography data) on the relation
between myocardial flow reserve and viability. As inclusion
criteria, all patients had regional left ventricular dysfunction at
rest. Exclusion criteria were unstable angina (making discon-
tinuation of therapy unethical), left ventricular hypertrophy,
valvular heart disease, diabetes mellitus (which may alter
coronary flow response independent of coronary artery dis-
ease), asthma and obstructive pulmonary disease (which rep-
resent a relative contraindication to dipyridamole stress) or
technically inadequate acoustic window (which precludes eval-
uation of left ventricular function by the echocardiographic
technique). In all patients, coronary angiography documented
significant coronary artery disease: single-vessel in 14 patients,
double-vessel in 2 and triple-vessel in 1 patient. All patients
were studied in the absence of antianginal therapy in random
order and on different days. Within 2 weeks, each patient had
undergone baseline echocardiography, dipyridamole stress
echocardiography and a coronary flow reserve study by PET.
Caffeine and theophylline derivatives were withheld at least
12 h before dipyridamole tests to prevent interference with the
hyperemic effect of dipyridamole.
Baseline echocardiographic examination. Two-dimensional
echocardiograms were obtained by using commercially avail-
able imaging systems. Echocardiographic images were digitally
acquired as well as recorded on videotape for subsequent
playback and analysis. According to the recommendations of
the American Society of Echocardiography (6), segmental wall
motion was semiquantitatively graded as follows: 1 5 normal;
0 5 hyperkinetic, increased endocardial motion and thicken-
ing; 2 5 hypokinetic, marked reduction of endocardial motion
and thickening; 3 5 akinetic, virtual absence of inward motion
and thickening; and 4 5 dyskinetic, paradoxic wall motion
away from the center of the left ventricle in systole. Regional
wall motion score (RWMS) was individually calculated for
each segment. Inadequately visualized segments (i.e., without
complete endocardial delineation) were not scored. To recon-
cile the 16-segment model proposed by the American Society
of Echocardiography (6) and generally adopted in stress
echocardiography with the limited spatial resolution of PET
imaging, we considered only three regions—anterior septum,
anterior wall and posterolateral wall—according to the 11-
segment model of the left ventricle previously adopted in
correlative studies on two-dimensional echocardiography with
PET (4). Each region was divided into three segments: proxi-
mal, middle and apical.
Low dose dipyridamole stress echocardiographic test.
Two-dimensional echocardiography and 12-lead ECG moni-
toring were performed in combination with dipyridamole
infusion (0.56 mg/kg body weight over 4 min) (7). In the
baseline studies as well as during stress, all standard echocar-
diographic views were obtained when possible. During the
procedure, the blood pressure and the ECG were recorded
each minute. The videotapes were analyzed by a cardiologist-
echocardiographer who had no knowledge of the clinical,
angiographic or scintigraphic data. The low level of intraob-
server and interobserver variability between experienced ob-
servers in our laboratory has been documented (8) and is
probably linked to previous extensive experience in joint
reading and development of a priori reading criteria, thus
overcoming the otherwise more substantial variability among
independent expert readers (9). A digital acquisition of images
of interest was obtained with a side by side display of rest and
peak stress images in a cine-loop mode, either on-line or
off-line by an array processor–based computer for medical
image processing (Mipron, Kontron). RWMS was derived for
rest and peak stress (0 to 1 min after the end of infusion)
echocardiograms in every segment in each patient, as previ-
ously described for the baseline echocardiographic examina-
tion. Each analyzed segment could belong to only one of the
following predefined subsets: 1) normal (RWMS rest 5 1;
RWMS dipyridamole 5 1); 2) ischemic or worsening (RWMS
rest $1; RWMS dipyridamole . rest); 3) responder (RWMS
rest .1; RWMS dipyridamole , rest); 4) nonresponder or fixed
(RWMS rest .1; RWMS dipyridamole 5 rest).
Regional myocardial blood flow study. We used a two-ring
positron tomograph (ECAT III, Siemens/CTI) that provides
three simultaneous cross sections of the heart (two from the
primary planes and one from the interplane). Regional myo-
cardial blood flow was assessed with 13N-ammonia. Tracer (15
to 20 mCi) was infused as a slow bolus over 10 to 20 s. Dynamic
tomographic data acquisition started simultaneously, as previ-
ously described (10). After acquisition of the baseline study, a
period of 50 min was allowed for the physical decay of
13N-ammonia. Thereafter, dipyridamole (0.56 mg/kg in 4 min)
was infused intravenously under continuous ECG monitoring.
The second injection of 13N-ammonia was started 2 to 3 min
after the end of dipyridamole infusion and the dynamic
tomographic data acquisition followed the same protocol as
that of the baseline study. To antagonize the effects of dipyr-
idamole, aminophylline (120 to 240 mg) was injected 3 min
after the dipyridamole 13N-ammonia injection in all patients.
In each patient, the two planes that better represented the left
ventricular walls were analyzed. Each tomographic plane was
divided into three regions: septal, anterior and posterolateral.
Abbreviations and Acronyms
ECG 5 electrocardiogram, electrocardiographic
PET 5 positron emission tomography (tomographic)
RWMS 5 regional wall motion score
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Images were analyzed by using circumferential profiles. The
program normalized 13N-ammonia counts within each myocar-
dial segment to the maximal activity. Segment activity was then
expressed as percent of maximal myocardial activity. A group
of segments remote from the infarct zone that had normal wall
motion by echocardiography and a normal feeding coronary
artery served as reference for control segmental 13N-ammonia
uptake. Absolute myocardial blood flow was computed accord-
ing to a method previously validated in our laboratory (10) and
described elsewhere (4). The absolute value of myocardial
blood flow was expressed as ml/min per g. Coronary reserve
was calculated as the ratio between dipyridamole and baseline
coronary blood flow.
Statistical analysis. A preliminary analysis was performed
to determine if a segment by segment analysis of the data was
appropriate in the absence of any consistent intrapatient
correlations of the segment data. A total of 72 possible
correlations between the 85 left ventricular segments were
examined at rest and after dipyridamole infusion for perfusion
and echocardiography. Because there were no consistent cor-
relations (p $ 0.05), the segment was used as the unit of
analysis. Values are expressed as mean value 6 SD. Intergroup
comparisons were performed by paired t test. Multiple group
comparisons (per-segment analysis) were performed with anal-
ysis of variance, and the Newman-Keuls test for individual
comparisons between groups was applied. A p value , 0.05
was considered statistically significant.
Results
Individual demographic, rest echocardiographic and angio-
graphic data of the study patients are summarized in Table 1.
Because nine PET segments were obtained for each of the 17
patients studied, the maximal theoretic number of analyzable
segments should total 153. However, because only the best two
of the three planes obtainable by PET were analyzed, the
maximal theoretic number of interpretable segments was only
102. Of these 102 segments, 16 were excluded because subop-
timal echocardiographic imaging, precluded reliable assess-
ment of the regional wall motion. Of the remaining 86
segments, 40 were dyssynergic and 46 normal at baseline
echocardiography. In one normal segment, a new dyssynergy
developed during low dose dipyridamole infusion in a region
with normal rest function fed by a critically stenosed coronary
artery. This segment was excluded from the analysis of flow
data. Therefore, we included in the data analysis the 40
dyssynergic and 45 normal control segments.
Baseline echocardiography. By inclusion criteria, all pa-
tients had regional dyssynergy in the rest echocardiogram.
Mean ejection fraction (by contrast ventriculography, area-
length method) was 0.44 6 0.1. Among the 40 segments with
baseline dyssynergy, 18 were akinetic and 22 hypokinetic.
Stress echocardiography. The systemic hemodynamic re-
sponse to dipyridamole infusion is reported in Table 2. There
was only a slight increase in heart rate, leading to an ;30%
increase in rate-pressure product from baseline. Of the 85
considered segments, 45 showed a normal, 9 an ischemic, 11 a
responder, and 20 a nonresponder pattern, as previously
defined. Nine segments that were hypokinetic in rest basal
conditions worsened during low dose dipyridamole infusion.
Myocardial blood flow. The 40 segments with baseline
dyssynergy had an average flow of 0.66 6 0.27 ml/min per g at
rest and 1.13 6 0.93 ml/min per g after dipyridamole (p ,
0.01). The 45 segments with normal baseline function had a
mean rest flow of 0.83 6 0.22 ml/min per g and 1.87 6
0.90 ml/min per g after dipyridamole (p , 0.01) (Table 3).
Correlation between stress echocardiographic and PET
findings. To build a flow-function relation during vasodilata-
tor stress in the four described functional patterns, the flow
behavior of all segments included in the analysis was assessed.
Normal segments had a coronary flow reserve of 2.30 6 1.15.
The corresponding functional pattern was a normal contrac-
tion becoming hyperkinetic during stress (Fig. 1). The nine
Table 1. Clinical, Echocardiographic and Angiographic Features of
the Study Patients
Pt
No.
Age (yr)/
Gender
Prev
MI
Coronary Angiography
(% stenosis)
EF
(%)LAD LCx RCA
1 55/M Non-Q 100 0 0 40
2 62/F Q 0 90 0 44
3 68/M Q 100 0 0 48
4 57/M Q 100 0 0 45
5 58/M Q 95 0 0 46
6 65/M Q 100 0 0 39
7 61/F Q 99 90 75 29
8 58/M Non-Q 0 75 0 53
9 56/M Non-Q 0 80 0 38
10 70/M Non-Q 100 0 0 51
11 52/M Q 100 0 0 52
12 51/M None 90 0 0 56
13 45/F None 90 0 0 54
14 67/F Non-Q 100 0 0 45
15 65/M Q 100 0 0 55
16 63/M Q 75 100 0 24
17 54/M Q 75 0 75 50
EF 5 ejection fraction; F 5 female; LAD 5 left anterior descending
coronary artery; LCx 5 left circumflex coronary artery; M 5 male; Prev MI 5
previous myocardial infarction; Pt 5 patient; Q 5 Q wave; RCA 5 right
coronary artery.
Table 2. Hemodynamic Changes During Stress
Echocardiographic Testing
Baseline Dipyridamole
SBP (mm Hg) 135 6 19 141 6 25
DBP (mm Hg) 82 6 7 84 6 9
HR (beats/min) 68 6 15 88 6 18*
RPP (mm Hgzbeats/min) 9,213 6 2,534 12,623 6 4,636*
*p , 0.05 versus baseline. Data are expressed as mean value 6 SD. DBP 5
diastolic blood pressure; HR 5 heart rate; RPP 5 rate-pressure product; SBP 5
systolic blood pressure.
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ischemic segments, with rest dysfunction, had a rest flow that
did not change after dipyridamole (Table 3), yielding a coro-
nary flow reserve of 1.37 6 0.60 (p , 0.01 vs. normal
segments). These segments showed a downsloping flow-
function curve during stress (Fig. 1), with worsening of func-
tion (Table 4) and no increase in flow. In segments with
abnormal rest function and no ischemia elicited by dipyrida-
mole infusion, rest regional wall motion score was 2.5 6 0.5 in
responders and 2.6 6 0.5 in nonresponders (Table 4). Rest
flow also was similar in responders and nonresponder seg-
ments (Table 3), whereas the peak dipyridamole flow was
significantly higher (p , 0.01) in responders than in nonre-
sponders (Table 3). Coronary flow reserve was significantly
higher in responders than in nonresponders (2.85 6 2.25 vs.
1.36 6 0.64, p , 0.01). Segments with a responder pattern
showed an upsloping flow-function curve during stress (Fig. 1),
with increased flow (Table 3) and function (Table 4) after
dipyridamole. Segments with a nonresponder pattern showed a
flat flow-function curve during stress (Fig. 1), with no signifi-
cant change in either flow or function after dipyridamole
(Tables 3 and 4).
Discussion
A spectrum of mechanical and flow responses after coro-
nary vasodilation can be associated with a similar level of
absolute regional rest flow and reduced rest function. Myocar-
dial segments with rest dysfunction and a contractile reserve
elicitable by a vasodilator stress more often exhibit a residual
flow reserve, whereas segments with a fixed or a worsening
mechanical response during stress show a flat flow response.
Flow-function relation during vasodilator stress. The inte-
grated assessment of regional function by two-dimensional
echocardiography and regional flow measurement by PET
allowed identification of four flow-function patterns, associ-
ated with distinct pathophysiologic responses: normal, isch-
emic, viable and necrotic.
In the normal segments, a normal/hyperkinetic contraction
pattern was associated with a 250% increase in regional flow.
This upsloping flow-function curve (Fig. 1) was characterized
by an increase in function with a more substantial increase in
flow. Previous studies (11,12) have shown that only a modest
inotropic effect on regional and global left ventricular function
is detectable with dipyridamole infusion, consistent with the
established physiologic finding that functional performance
increases with higher than normal perfusion levels, but what-
ever the increase in flow—up to two to four times rest
values—the thickening does not increase by .50% (2,3,13).
In the ischemic segments, a worsening of regional function
was associated with no significant increase in regional flow.
This downsloping flow-function curve (Fig. 1) was character-
ized by a further worsening of baseline function with almost no
increase in flow. This finding is also consistent with experimen-
tal and clinical data. In the presence of coronary stenosis, the
administration of a coronary vasodilator can induce a true
imbalance between supply and demand, as blood flow in the
distribution of a coronary artery actually decreases as a result
of a “steal” phenomenon (14). On average, in the ischemic
segments of our patients, blood flow did not decrease, a finding
Table 3. Regional Myocardial Blood Flow at Baseline and
During Dipyridamole
Normal
Segments
(n 5 45)
Basally Dyssynergic Segments
Responder
(n 5 11)
Ischemic
(n 5 9)
Nonresponder
(n 5 20)
Baseline
(ml/min per g)
0.83 6 0.22 0.69 6 0.3 0.67 6 0.29 0.64 6 0.24
Dipyridamole
(ml/min per g)
1.87 6 0.90 1.89 6 1.43 0.79 6 0.23 0.87 6 0.51
p value , 0.01 , 0.01 NS NS
Data are expressed as mean value 6 SD.
Figure 1. Flow-function relation in patients with
chronic coronary artery disease and reduced re-
gional function. Regional transmural blood flow
(x-axis) was measured by PET; RWMS (y-axis) was
measured semiquantitatively by two-dimensional
echocardiography, ranging from dyskinesia up to
normal and hyperkinesia. Segments with reduced
rest function show fairly similar values of rest flow
(open circles) but obviously different patterns dur-
ing vasodilator stress (closed circles): upsloping
response in responders; flat response in nonre-
sponders; downsloping response in ischemic seg-
ments. Values are expressed as mean value (cir-
cles) 6 1 SD (bars).
Table 4. Regional Myocardial Wall Motion Score at Baseline and
During Dipyridamole
Normal
Segments
(n 5 45)
Basally Dyssynergic Segments
Responder
(n 5 11)
Ischemic
(n 5 9)
Nonresponder
(n 5 20)
Baseline 1 2.5 6 0.5 2 6 0.5 2.6 6 0.5
Dipyridamole 0 1.2 6 0.4 3.1 6 0.6 2.6 6 0.5
p value , 0.01 , 0.01 , 0.01 NS
Data are expressed as mean value 6 SD.
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consistent with a transmural or vertical steal, with subepicar-
dial overperfusion in the presence of an absolute reduction in
subendocardial flow (15). The expected physiologic conse-
quence of this mechanism is a flat blood flow response, because
PET measurement, due to inherent limitations in axial sam-
pling capability and spatial resolution, averages out a reduction
in subendocardial and an increase in subepicardial flow (16).
Overall regional function is reduced, because the subendocar-
dial layer contributes to 67% of regional thickening, whereas
normally there is only a small contribution of the subepicar-
dium to overall thickening (17). We (4) previously observed
the blunted flow response in segments becoming ischemic
during stress in patients with single-vessel disease and normal
rest function who were also studied by two-dimensional echo-
cardiography and PET during vasodilator stress. In that study,
we found that dipyridamole-induced regional dysfunction is
associated with a reduction in coronary flow reserve that is
more severe when the dipyridamole-induced dyssynergy ap-
pears earlier during the test. We labeled segments with stress-
induced worsening of function as ischemic to differentiate their
mechanical response from that of responders. In reality, seg-
ments with worsening function during stress are potentially
viable and capable of recovering function after revasculariza-
tion.
In the viable segments, an increase in regional coronary flow
was mirrored by an increase in function of a segment with
baseline dyssynergy. This upsloping flow-function curve (Fig.
1) was characterized by an increase in function and flow. In
contrast to the upsloping pattern of normal segments, however,
the flow-function curve was shifted rightward; that is, for any
given flow the function was depressed, both at baseline and
during stress. The possibility of recruiting flow reserve in a
segment with rest dysfunction may appear paradoxic, but its
occurrence has been clearly shown in experimental (18–20)
and clinical (5,21) studies. Residual flow reserve has been
documented in patients with severe coronary stenosis and
depressed baseline flow in studies employing either left ven-
tricular injection of albumin microspheres (21) or 13N-
ammonia (5) as a flow tracer and either papaverine (21) or
dipyridamole (5) as a pharmacologic stimulus. This increase in
flow is associated with an increase in function through either a
hemodynamic effect of increased flow (Gregg effect [22,23]) or
a flow-independent direct cardioprotective effect of endoge-
nous adenosine accumulation (24).
In the necrotic segments, rest dysfunction remained un-
changed after vasodilator stress, with no flow or function
response. This flat flow-function curve (Fig. 1) was character-
ized by no significant change in either flow or function during
stress. The likely physiologic correlate of this response is scar
tissue. Connective tissue replaces subendocardial or transmu-
ral myocytes, preventing contractile response, and the coro-
nary microvascular bed, blunting the flow response.
Comparison with previous studies. The functional re-
sponse to dipyridamole of basally dysfunctioning segments has
been correlated with functional recovery after coronary revas-
cularization and thallium uptake (25,26). Dipyridamole-
induced functional recovery shows the same accuracy, with a
slightly lower sensitivity and slightly higher specificity, than
dobutamine-echocardiography for predicting spontaneously
occurring functional recovery after acute myocardial infarction
(27). Only one previous study (28) provided a simultaneous
assessment of regional wall motion and myocardial perfusion,
the latter evaluated by contrast echocardiography. In that
study, Rovai et al. showed that residual contractile reserve of
asynergic, infarcted segments is associated with either basally
preserved myocardial perfusion or decreased perfusion defect
by low dose dipyridamole. The present study confirms and
expands that previous observation, establishing in more quan-
titative terms the relation between myocardial perfusion and
contractile response in viable myocardium. In fact, myocardial
contrast echocardiography provides only an index of myocar-
dial perfusion and to date does not allow the quantitative
assessment of myocardial absolute flow (29) that was obtained
in the present study by PET imaging (16).
Limitations of the study. We adopted one dose regimen
(the standard 0.56 mg/kg over 4 min) for both PET and
two-dimensional echocardiographic studies. This dosage was
originally proposed by Gould (30) and adopted in first-
generation dipyridamole stress echocardiography (7); these
stress studies later used high dose dipyridamole (31) and are
currently performed with coadministration of atropine (32).
The standard dose cannot guarantee maximal coronary vaso-
dilation in all patients and is not ideal for the diagnostic use of
stress echocardiography, which requires a higher dose to
increase sensitivity (31) and a lower dose to selectively explore
myocardial viability without inducing ischemia (26). However,
the aim of our study was to establish the flow-function corre-
lates during a given vasodilator stimulus; therefore, we chose
the standard dose as a convenient trade-off, offering an ade-
quate hyperemic stress associated with the full spectrum of
mechanical responses, from worsening to improvement (33).
The coronary flow and myocardial function studies were
performed on separate days. Ideally, simultaneous assessment
would have been preferred. Practically, it was impossible to
reconcile the need for optimal echocardiographic imaging
(usually performed in the left lateral decubitus position) and
the need for optimal PET imaging (in the supine position into
the gantry). Because dipyridamole stress has high short-term
reproducibility (31), this limitation should have not affected
the study results to any significant extent.
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